Baptist Health Lexington

Charles E Rose, III

Principal Investigator

Sanghamitra Satapathy


Want to join the trial?

Choose a location to contact our Clinical Trial Coordinator and to discuss potential opportunities.

Email Coordinator
SUPERNOVA: D7000C00001 A Phase I/III Randomized, Double-blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment

AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.

The aim of the Phase I/III study (Parent Study) will be to evaluate the safety, efficacy and neutralizing activity of AZD3152 compared with comparator for pre exposure prophylaxis of COVID-19, and separately evaluate the safety and PK of AZD5156, a combination of AZD3152 and AZD1061.

Learn more at

Eligibility Criteria
Inclusion Criteria:
Healthy participants according to medical history, physical examination, baseline safety laboratory tests, and screening parameters, according to the judgment of the investigator, with no concomitant disease or concomitant medication (except for medication specifically permitted by the protocol).
Age 18 to 55 years at the time of signing the informed consent.
Negative rapid antigen test at Visit 1.
Weight ≥ 45 kg and ≤ 110 kg at screening.

Exclusion Criteria:
Women who are pregnant, lactating, or of childbearing potential and not using a highly effective method of contraception or abstinence from at least 4 weeks prior to study intervention administration and until at least 6 months after study intervention administration.
Known hypersensitivity to any component of the study intervention.
Previous hypersensitivity or severe adverse reaction following administration of a mAb.
Acute (time-limited) or febrile (temperature ≥ 38.0°C [100.4ºF]) illness/infection on day prior to or day of planned dosing; participants excluded for transient acute illness may be dosed if illness resolves within the screening period or may be rescreened once.
Blood drawn in excess of a total of 450 mL (1 unit) for any reason within 30 days prior to Visit 1.
Clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venipuncture.
Receipt of immunoglobulin (non-COVID related) or blood products within 6 months prior to Visit 1.
Previous receipt of a mAb against SARS-CoV-2.
Receipt of a COVID-19 vaccine within 3 months prior to Visit 1.
Receipt of a COVID-19 antiviral for prophylaxis within 3 months prior to Visit 1
COVID-19 within 3 months prior to Visit 1 (confirmed either by laboratory testing or a rapid test [including at home testing]).
Receipt of any IMP in the preceding 90 days or expected receipt of IMP during the period of study follow-up, or concurrent participation in another interventional study.
Known or suspected congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy, including any course of glucocorticoid therapy exceeding 2 weeks of prednisone or equivalent at a dose of 20 mg daily or every other day within 6 months prior to screening.
Active infection with hepatitis B or C.
Serum creatinine, AST, or ALT above 1.5 × ULN at screening